Product description

Pituitary pars intermedia dysfunction (PPID), also referred to as equine Cushing’s disease, is one of the most common endocrine disorders in horses. PPID originates from a degeneration of the hypothalamic dopamine-producing neurons. The lack of sufficient dopamine causes the horse's pituitary gland, which utilizes hormones to control body functions, to work overtime. This can lead to a variety of problems for horses, ranging from delayed shedding to loss of muscle mass.

Some Clinical Signs of PPID

• Loss of seasonal hair coat shedding
• Decreased performance
• Change in attitudes
• Recurrent infections
• Abnormal sweating
• Laminitis

When it comes to treating PPID in horses, the earlier the better. Using Prascend as part of PPID management protocol can help reduce the clinical signs of PPID to improve the quality of life of your horse. Prascend is a dopamine agonist, it acts to replace the dopamine that is missing from the intermediate lobe of the pituitary gland in horses with PPID. By binding to the dopamine receptor, Prascend decreases the production of hormones by the intermediate lobe.

Prascend tablets are rectangular, light-red, half-scored tablets containing 1 mg pergolide, as pergolide mesylate, a dopamine receptor agonist for oral use in horses only.

Active ingredients

1 mg of pergolide mesylate.

Indications for use

Prascend tablets are indicated for the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing’s Disease) in horses.

Administration and dosage

Preserved and protected in foil blister packs, the single-scored tablets make it simple to adjust dosage. Administer orally at a starting dose of 2 mcg/kg once daily. Dosage may be adjusted to effect, not to exceed 4 mcg/kg daily. Prascend tablets should not be crushed due to the potential for increased human exposure and care should be taken to minimize exposure when splitting tablets.

Prescribing information